Abstract: Telaglenastat (CB-839) is a potent, selective, and orally bioavailable inhibitor of glutaminase (GLS), a critical enzyme in glutamine metabolism. In Non-Small Cell Lung Cancer (NSCLC), metabolic reprogramming often leads to "glutamine addiction," making GLS an attractive therapeutic target. This review explores the pharmacological activity, molecular mechanism, and structure-activity relationship of CB-839. It highlights its efficacy in specific NSCLC genetic subsets, such as those with KRAS, LKB1, and KEAP1 mutations, and its ability to overcome resistance to standard therapies. Current limitations, including resistance mechanisms and limited monotherapy efficacy, are discussed alongside future perspectives focusing on combination strategies with immunotherapies and other metabolic inhibitors.
1. Introduction
Cancer cells frequently undergo metabolic reprogramming to support rapid proliferation and survival in nutrient-depleted environments. A prominent feature of this rewiring is "glutamine addiction," wherein tumors rely heavily on exogenous glutamine to replenish tricarboxylic acid (TCA) cycle intermediates and support the biosynthesis of nucleotides, lipids, and proteins [56][86]. Glutaminase (GLS) is the rate-limiting enzyme that catalyzes the conversion of glutamine to glutamate, and its upregulation is a hallmark of various aggressive cancers, including Non-Small Cell Lung Cancer (NSCLC) [56]. To exploit this metabolic vulnerability, telaglenastat (CB-839) was developed as a potent, selective, and orally bioavailable inhibitor of GLS1 [15][19]. This review synthesizes current research on CB-839, focusing on its application, mechanisms, and clinical potential in the treatment of NSCLC.
2. Pharmacological Activity
In NSCLC, CB-839 exhibits significant pharmacological activity by disrupting glutamine catabolism, thereby starving tumor cells of the carbon intermediates essential for TCA cycle progression [4]. The pharmacological efficacy of CB-839 is highly dependent on the tumor's genetic profile. Preclinical studies have demonstrated that NSCLC tumors harboring co-mutations in KRAS, STK11/LKB1, and KEAP1 exhibit an enhanced dependence on glutamine metabolism, rendering them particularly sensitive to CB-839 [4]. Furthermore, CB-839 has shown the ability to reverse acquired resistance to standard NSCLC treatments, including cisplatin and the targeted EGFR inhibitor osimertinib [41]. Beyond direct tumor inhibition, CB-839 modulates the tumor microenvironment (TME). By reducing the tumor's consumption of glutamine, the drug increases systemic and TME glutamine concentrations, providing tumor-infiltrating lymphocytes (TILs) with greater access to this conditionally essential amino acid. This metabolic rebalancing enhances CD8+ T-cell proliferation and activation, promoting an anti-tumor immune response [7].
3. Molecular Mechanism of Action
CB-839 functions as a selective, noncompetitive allosteric inhibitor of the GLS enzyme [15]. At the molecular level, it binds specifically to the dimer interface of GLS. This binding event prevents the tetramerization of the enzyme, a structural conformation that is strictly required for its catalytic activation, thereby locking GLS in an inactive state [11]. By inhibiting the conversion of glutamine to glutamate, CB-839 triggers a cascade of metabolic disruptions. It depletes the intracellular pool of glutamate and subsequent TCA cycle intermediates, impairs the synthesis of the antioxidant glutathione (GSH), and induces an accumulation of intracellular reactive oxygen species (ROS), ultimately leading to metabolic catastrophe and tumor cell death [4][86].
4. Structure-Activity Relationship (SAR)
The structural design of CB-839 was optimized to overcome the poor solubility and bioavailability associated with earlier GLS allosteric inhibitors, such as BPTES [11]. A critical feature of CB-839's structure-activity relationship is the incorporation of a terminal electron-withdrawing trifluoromethoxy group. This specific modification serves a dual purpose: it increases the integral lipophilicity of the molecule, and it improves the electronegativity of the pyridazinyl nitrogen atoms [11]. These electronic enhancements result in strengthened hydrogen bond interactions at the GLS dimer interface, significantly improving the compound's binding affinity, inhibitory potency, and pharmacokinetic profile for clinical use [11].
5. Current Limitations
Despite its potent preclinical profile, the clinical application of CB-839 faces several limitations. A primary criticism is its lack of robust single-agent activity, which often necessitates its use in combination regimens to achieve meaningful clinical responses [52]. Additionally, tumor cells can develop resistance to GLS inhibition through compensatory metabolic rewiring. Known resistance mechanisms include the upregulation of pyruvate carboxylase (which replenishes the TCA cycle by converting pyruvate directly into oxaloacetate), increased expression of asparagine synthetase, and downregulation of the glutamate/cystine (xCT) antiporter [9]. In NSCLC, variable sensitivity to CB-839 has also been linked to the ability of individual cancer cells to generate pyruvate from alanine, allowing them to bypass the metabolic blockade imposed by glutamine deprivation [4].
6. Future Perspectives
The future development of telaglenastat in NSCLC is heavily focused on rational combination therapies. Given its ability to revitalize T-cell activity in the TME, combining CB-839 with immune checkpoint inhibitors (e.g., nivolumab or pembrolizumab) is a highly promising strategy. Clinical trials, such as the KEAPSAKE trial (evaluating telaglenastat combined with pembrolizumab and chemotherapy in KEAP1/STK11/LKB1-mutated NSCLC) and the CX-839-004 trial, are actively investigating these synergistic effects [1][3][7]. Another promising approach involves dual metabolic targeting to overcome resistance. For example, combining CB-839 with L-cycloserine, an inhibitor of alanine aminotransferase, has been shown to increase tumor response by blocking compensatory pyruvate generation [4]. Furthermore, recent evidence suggests that common drugs like aspirin can upregulate GLS1, exposing a metabolic vulnerability that can be exploited by CB-839 [21]. Continued biomarker-driven research will be essential to identify the NSCLC patient subpopulations most likely to benefit from these innovative combination strategies.
